On December 15, 2023, Onconetix appointed Christian Brühlmann, 47, as Chief Strategy Officer of Onconetix, effective immediately, to serve until the election and qualification of his successor or his earlier death, resignation or removal. Mr. Brühlmann co-founded Proteomedix and served as its Chief Financial and Operations Officer from March 2010 until November 2018. Beginning in December 2018, Mr. Brühlmann served as Proteomedix?s Chief Business Officer until the consummation of the Share Exchange.

Mr. Brühlmann is qualified to serve as Chief Strategy Officer because of his extensive experience with business strategy and familiarity with Proteomedix. Mr. Brühlmann has no family relationships with any of Onconetix?s directors or executive officers, and he is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Brühlmann and any other persons pursuant to which he was selected as an officer. The Compensation Committee of the Board (the ?Compensation Committee?) will consider compensatory arrangements for Mr. Brühlmann at a later date.

On December 15, 2023, Onconetix appointed Ralph Schiess, 45, as Chief Science Officer of Onconetix, effective immediately, to serve until the election and qualification of his successor or his earlier death, resignation, or removal. Dr. Schiess co-founded Proteomedix in March 2010 and served as its Chief Executive Officer from its inception until December 2019. Dr. Schiess then served as Proteomedix?s Chief Scientific Officer from January 2020 to May 2023.

Dr. Schiess returned to his role as Chief Executive Officer in June 2023 and served until the consummation of the Share Exchange. Dr. Schiess is qualified to serve as Chief Science Officer because of his extensive experience in the pharmaceutical industry and familiarity with Proteomedix. .

Schiess has no family relationships with any of Onconetix?s directors or executive officers, and he is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Schiess and any other persons pursuant to which he was selected as an officer. The Compensation Committee will consider compensatory arrangements for Dr. Schiess at a later date.